SAB Biotherapeutics Statistics
Total Valuation
SABS has a market cap or net worth of $22.07 million. The enterprise value is $22.78 million.
Important Dates
The next estimated earnings date is Wednesday, November 5, 2025, after market close.
| Earnings Date | Nov 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
SABS has 10.41 million shares outstanding. The number of shares has increased by 21.75% in one year.
| Current Share Class | 10.41M |
| Shares Outstanding | 10.41M |
| Shares Change (YoY) | +21.75% |
| Shares Change (QoQ) | +0.03% |
| Owned by Insiders (%) | 18.09% |
| Owned by Institutions (%) | 9.67% |
| Float | 7.56M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 171.60 |
| Forward PS | n/a |
| PB Ratio | 1.64 |
| P/TBV Ratio | 1.84 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 198.58 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.87, with a Debt / Equity ratio of 0.53.
| Current Ratio | 0.87 |
| Quick Ratio | 0.54 |
| Debt / Equity | 0.53 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -147.88 |
Financial Efficiency
Return on equity (ROE) is -127.48% and return on invested capital (ROIC) is -74.79%.
| Return on Equity (ROE) | -127.48% |
| Return on Assets (ROA) | -56.81% |
| Return on Invested Capital (ROIC) | -74.79% |
| Return on Capital Employed (ROCE) | -215.00% |
| Revenue Per Employee | $1,821 |
| Profits Per Employee | -$588,177 |
| Employee Count | 63 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -24.29% in the last 52 weeks. The beta is 0.55, so SABS's price volatility has been lower than the market average.
| Beta (5Y) | 0.55 |
| 52-Week Price Change | -24.29% |
| 50-Day Moving Average | 2.28 |
| 200-Day Moving Average | 2.26 |
| Relative Strength Index (RSI) | 47.01 |
| Average Volume (20 Days) | 84,009 |
Short Selling Information
The latest short interest is 440,483, so 4.23% of the outstanding shares have been sold short.
| Short Interest | 440,483 |
| Short Previous Month | 501,956 |
| Short % of Shares Out | 4.23% |
| Short % of Float | 5.83% |
| Short Ratio (days to cover) | 3.61 |
Income Statement
In the last 12 months, SABS had revenue of $114,698 and -$37.06 million in losses. Loss per share was -$3.99.
| Revenue | 114,698 |
| Gross Profit | -30.02M |
| Operating Income | -41.82M |
| Pretax Income | -40.32M |
| Net Income | -37.06M |
| EBITDA | -38.52M |
| EBIT | -41.82M |
| Loss Per Share | -$3.99 |
Full Income StatementBalance Sheet
The company has $5.71 million in cash and $6.42 million in debt, giving a net cash position of -$705,092 or -$0.07 per share.
| Cash & Cash Equivalents | 5.71M |
| Total Debt | 6.42M |
| Net Cash | -705,092 |
| Net Cash Per Share | -$0.07 |
| Equity (Book Value) | 12.02M |
| Book Value Per Share | 1.29 |
| Working Capital | -1.37M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$30.77 million and capital expenditures -$155,677, giving a free cash flow of -$30.93 million.
| Operating Cash Flow | -30.77M |
| Capital Expenditures | -155,677 |
| Free Cash Flow | -30.93M |
| FCF Per Share | -$2.97 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -36,463.03% |
| Pretax Margin | -32,306.71% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SABS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -21.75% |
| Shareholder Yield | -21.75% |
| Earnings Yield | -167.89% |
| FCF Yield | -140.13% |
Analyst Forecast
The average price target for SABS is $9.50, which is 348.11% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $9.50 |
| Price Target Difference | 348.11% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 98.78% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 5, 2024. It was a reverse split with a ratio of 1:10.
| Last Split Date | Jan 5, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
SABS has an Altman Z-Score of -10.34 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -10.34 |
| Piotroski F-Score | 1 |
